Paris (ots/PRNewswire) - - Toujeo® provides a flatter profile than insulin degludec with less within-day fluctuations - Sanofi (http://www.sanofi.com) presented today the full results of a pharmacokinetic / pharmacodynamic (PK/PD) study with Toujeo® (insulin glargine 300 Units/mL) and insulin degludec 100 Units/mL ...
Paris (ots/PRNewswire) - Further comparative data expected from ongoing head-to-head clinical trial Sanofi (http://www.sanofi.com) announced today the key results of a new pharmacokinetic / pharmacodynamic (PK/PD) study in people with type 1 diabetes comparing Toujeo® (insulin glargine 300 Units/mL) to insulin ...
Paris (ots/PRNewswire) - - Benefits on adherence and HbA1c to be validated in a real-world setting - Sanofi (http://www.sanofi.com) announced today that adults with type 2 diabetes treated with Toujeo® (insulin glargine 300 Units/mL) experienced a consistently lower rate of confirmed or severe hypoglycemia both at ...
Paris (ots/PRNewswire) - Sanofi announced today the release of the new real world data assessing the use of Toujeo® (insulin glargine injection 300 Units/mL). The U.S. Predictive Health Intelligence Environment (PHIE) database, containing a substantial amount of patient level information, was analyzed to assess Toujeo in this real life setting. The study examined ...
Lyon, France (ots/PRNewswire) - - Sanofi Pasteur works with global partners to make available unparalleled quantities of affordable Inactivated Polio Vaccine (IPV) - Sanofi Pasteur, the vaccines division of Sanofi , announced today its further commitment to the international community's efforts to complete polio ...
Paris (ots/PRNewswire) - Two studies presented at World Diabetes Congress 2011 provide further evidence of the benefits to patients of early glycemic control on co-morbidities Sanofi announced today new results from sub-analyses of the First Basal INsulin Evaluation in Asia (FINE Asia) Registry study,[1] and the Cardiovascular Risk Evaluation in People with Type 2 ...
Paris (ots/PRNewswire) - - New findings from the pivotal TEMSO Phase III study presented today at the joint ECTRIMS / ACTRIMS Congress - - U.S. FDA Accepts New Drug Application for Teriflunomide for relapsing forms of MS - Sanofi and its subsidiary Genzyme announced today new data from the pivotal TEriflunomide ...
Paris (ots/PRNewswire) - - Findings from Two-Year Pivotal Phase III TEMSO Trial Published today in The New England Journal of Medicine - Sanofi and its subsidiary Genzyme announced today the publication of the pivotal Phase III TEMSO study with investigational once-daily oral medication teriflunomide in The New ...
Lyon, France (ots/PRNewswire) - - Vaccine strain used in the production of oral polio vaccines against type 3 poliovirus - Sanofi Pasteur, the vaccines division of Sanofi , announced today it is donating to the World Health Organization (WHO) a vaccine strain used for polio eradication. The biological material given by Sanofi Pasteur is the original viral seed used to ...
Paris (ots/PRNewswire) - - First Randomized Controlled Trial to Show That Basal Plus Regimen Provides more Effective Glycemic Control with Less Hypoglycemia Than with Aspart Premixed Insulin Sanofi announced today data presented at the 47th Annual Meeting of the European Association for the Study of Diabetes to show ...
Paris (ots/PRNewswire) - -- Nurses Worldwide are Encouraged to Enter an Exciting Recognition Program Which Showcases Their Creativity and Their Care Solutions/Practice Innovations -- Sanofi announced today the launching of the Care Challenge program. Care Challenge (http://www.care-challenge.com) is an online initiative developed by Sanofi in collaboration with nurses' ...
Lyon, France (ots/PRNewswire) - - Newcomer's Biopharmaceutical Experience to Further Develop European Joint-Venture - MSD, known as Merck in the United States and Canada , and Sanofi Pasteur, the vaccines division of Sanofi , the two partner companies in Sanofi Pasteur MSD, announce today the appointment of Dr. Jean-Paul Kress as President of Sanofi Pasteur MSD, ...
Paris (ots/PRNewswire) - - Human and in vivo Studies Indicate Lantus(R) Metabolites do not ConferCarcinogenic Potential via IGF-1 Receptor Activation Sanofi announced at the 71st American Diabetes Association Scientific Sessions 2011 the results of four studies[1,2,3,4] indicating that the effect of Lantus(R) (insulin glargine) metabolites on the IGF-1 receptor is ...
Paris (ots/PRNewswire) - Sanofi announced today, at the 71st Scientific American Diabetes Association Sessions 2011, the results of three studies showing that people with diabetes using Sanofi insulins Lantus(R) and/or Apidra(R) with the insulin delivery device SoloSTAR(R) experienced greater treatment satisfaction, better quality of life and lower fear of hypoglycemia vs those using a premixed insulin product. The goal ...
LYON, France and SWIFTWATER, Pennsylvania, February 23, 2011 (ots/PRNewswire) -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group , today will participate in the first international bell-ringing event by a company listed on NYSE Euronext. The events will acknowledge past successes and future challenges in the battle to eradicate polio at the stock ...
Lyon, France (ots/PRNewswire) - Sanofi Pasteur, the vaccines division of sanofi-aventis Group , announced today that it is partnering with the International Vaccine Institute (IVI) to support the recently launched Dengue Vaccine Initiative (DVI). Sanofi Pasteur and the IVI will aim to raise awareness and to work to move dengue vaccination higher on the global health ...
Paris, November 5 (ots/PRNewswire) - Sanofi-aventis announced today that it is a partner in a new multidisciplinary atrial fibrillation research consortium, the "European Network for Translational research in Atrial Fibrillation" (EUTRAF), which has been awarded a EUR12 million grant to engage in atrial fibrillation (AF) research. The European consortium is ...
Lyon, France, November 4 (ots/PRNewswire) - Sanofi Pasteur, the vaccines division of sanofi-aventis Group , announced today that its dengue vaccine is in final stage of clinical development. Sanofi Pasteur's dengue vaccine, the world's most clinically advanced dengue vaccine candidate(1,2), entered its first phase 3 clinical study in Australia. This study is ...
Paris (ots/PRNewswire) - Sanofi-aventis announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta). ...
Paris (ots/PRNewswire) - Sanofi-aventis announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS). In this study, both doses of teriflunomide (7 and 14mg) significantly reduced annualized relapse rate (primary study endpoint) by 31% ...
Paris (ots/PRNewswire) - Sanofi-aventis announced today results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden. The first pooled analysis using patient-level data from randomized clinical trials demonstrated that adding ...
Paris (ots/PRNewswire) - Sanofi-aventis announced today the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the ...
Paris (ots/PRNewswire) - Sanofi-aventis announced today that results from the RealiseAF (Real-life global survey evaluating patients with Atrial Fibrillation) registry show that control of atrial fibrillation (AF) (defined by the 2006 ACC/AHA/ESC AF guidelines as either sinus rhythm or AF with heart rate at ...
Paris, August 30, 2010 (ots/PRNewswire) - Sanofi-aventis announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in patients with relapsing multiple sclerosis (RMS), thus achieving the primary endpoint in the TEMSO ...
Paris, August 29, 2010 (ots/PRNewswire) - Sanofi aventis announced today that the European Society of Cardiology (ESC) 2010 new Guidelines for the Management of Atrial Fibrillation (AF) have been released and recommend that Multaq(R) (dronedarone) should be used for maintenance of sinus rhythm as a first-line treatment option in all patients with paroxysmal and ...
Paris, June 7, 2010 (ots/PRNewswire) - Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent ...
Paris, May 12, 2010 (ots/PRNewswire) - Sanofi-aventis announced today the initiation of a multinational, randomized, double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10,000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during ...
Paris, March 30, 2010 (ots/PRNewswire) - Sanofi-aventis announced today that the National Institute for Health and Clinical Excellence (NICE) in England and Wales, has just published a new appraisal consultation document (ACD)[1] for Multaq(R) (dronedarone) indicating its intention to recommend Multaq(R) use for ...
Paris, November 30 (ots/PRNewswire) - - First New Anti-Arrhythmic Drug to be Approved in the European Union in the Last 10 Years Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the European Commission has granted marketing authorization for Multaq(R) (dronedarone - 400mg Tablets) in all 27 European member states. This approval follows the ...
Paris, November 16 (ots/PRNewswire) - - The RealiseAF Registry Will Help to Better Define and Understand the Cardiovascular Risk Profile of AF Patients and Characterize Their Cardiovascular Outcomes Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the launch of the RealiseAF registry (Real ...